Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Celsion Corp (CLSN)

Celsion Corp (CLSN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Celsion Corporation to Hold Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 15, 2022

LAWRENCEVILLE, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based...

CLSN : 1.9600 (unch)
Celsion Corporation Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)

LAWRENCEVILLE, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy...

CLSN : 1.9600 (unch)
Celsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

Novel Gene-Mediated Immunotherapy is Safe and Demonstrates an Acceptable Risk/Benefit Full Enrollment Expected by Third Quarter of 2022 ...

CLSN : 1.9600 (unch)
Advanced Clinical Trials Focus on Development of Vaccines to Prevent Ovarian Cancer Progression

Palm Beach, FL – May 18, 2022 – FinancialNewsMedia.com News Commentary – Companies in the Ovarian Cancer market are spending a lot of R&D on vaccine development, therapies and studies. For the past...

BIOV.CN : 0.0750 (unch)
BVAXF : 0.0563 (+5.43%)
CLSN : 1.9600 (unch)
IMGN : 31.23 (unch)
ZNTL : 15.76 (+3.75%)
BMY : 54.23 (+1.84%)
Celsion Corporation Highlights Pipeline Progress in Its Lead Development Candidates

PLACCINE DNA-based Vaccine in proof-of-concept non-Human Primate Studies Phase II study of GEN-1 in ovarian cancer 85% enrolled with full enrollment...

CLSN : 1.9600 (unch)
Celsion Corporation to Hold First Quarter 2022 Financial Results and Business Update Conference Call on Monday, May 16, 2022

LAWRENCEVILLE, N.J., May 09, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based...

CLSN : 1.9600 (unch)
Celsion Corporation Highlighted its PLACCINE Vaccine Platform Technology During Oral Presentation at the World Vaccine Congress

Proprietary, Formulated DNA Plasmid Vaccine Candidate Shows Neutralizing Activity Against 2 Strains of the COVID-19 Virus The Goal to Provide...

CLSN : 1.9600 (unch)
Celsion and Medidata Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial at 2022 AACR Annual Meeting

 Phase Ib dose-escalating OVATION I Study with GEN-1 in advanced ovarian cancer patients was well received at 2022 AACR Annual Meeting LAWRENCEVILLE,...

CLSN : 1.9600 (unch)
Celsion Corporation to Highlight its PLACCINE Platform Technology During Oral Presentation at the World Vaccine Congress

LAWRENCEVILLE, N.J., April 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage company focused on DNA-based immunotherapy...

CLSN : 1.9600 (unch)
Celsion Corporation Announces Closing of $7.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

LAWRENCEVILLE, NJ, April 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced the closing of its...

CLSN : 1.9600 (unch)

Barchart Exclusives

Ford Motor vs. Toyota: Which Hybrid EV Stock Is a Better Buy?
With hybrid EVs gaining popularity, let’s find out whether shares of Ford or Toyota are a better buy. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar